Bempedoic Acid tablets bulk supplier for pharma manufacturers

Bempedoic Acid Tablets 180 mg Suppliers & Bulk Manufacturers

Available Forms: Tablet

Available Strengths: 180 mg

Reference Brands: Nexletol(US & EU)

Bempedoic acid inhibits ATP citrate lyase, reducing cholesterol synthesis in the liver. It lowers LDL cholesterol levels, decreasing cardiovascular risk. Benefits include effective LDL reduction, fewer side effects compared to statins, and support for patients intolerant to statins, aiding long-term lipid management and cardiovascular disease prevention

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Bempedoic acid tablets, marketed as Nexletol, are approved in the US by the FDA and in the EU via EMA for adults with hyperlipidemia or atherosclerotic cardiovascular disease. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed trial data and manufacturing processes, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier submission, regulatory pathways, and market access, visit PharmaTradz. Ensuring compliance supports timely approval, safe use, and global availability of bempedoic acid tablets, helping improve lipid management and cardiovascular outcomes worldwide.

Bempedoic Acid Tablets — third party manufacturing & bulk supply

Bempedoic Acid Tablets 180 mg is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Bempedoic Acid Tablets is supplied as Tablet — an oral solid dosage form, so the indicative MOQ is 200,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Bempedoic Acid Tablets listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Bempedoic Acid Tablets →

Back to Listing

Frequently Asked Questions

Bempedoic Acid tablets is listed as Tablet in 180 mg. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Bempedoic Acid tablets is referenced against Nexletol(US & EU). Reference brands are shown for identification only and remain the property of their respective trademark owners.